Red Light Therapy for Aging Eyes: What the Studies Actually Show (2026)

A viral post claims red light therapy improved eyesight in 95-97% of people within two weeks. Those numbers are real, but they come from one 2008 study, and they don't mean what the post implies.

Evidence grade: C

A viral post claims red light therapy improved eyesight in 95-97% of people within two weeks. Those numbers are real, but they come from one 2008 study, and they don't mean what the post implies. Here is what the research on red and near-infrared light for the eyes actually measured.

Where the 95-97% figure comes from

In 2008 Boris and Tobias Ivandic published a case series of 203 patients with dry or wet age-related macular degeneration (AMD). 193 patients (328 eyes) received low-level laser therapy (780 nm, four sessions over two weeks), and the authors reported improved visual acuity in 95% of eyes with cataracts and 97% of eyes without cataracts. That is the source of the viral figure.

What to keep in mind:

It was a retrospective case series, not a randomized trial. The only comparison was 10 patients (20 eyes) given mock treatment, against 193 treated patients.
'Improved' meant a statistically significant change in visual acuity versus baseline, not restored eyesight.
The patients had diagnosed eye disease and were treated with a specific 780 nm laser in a clinic, not a consumer LED panel.
The result has not been reproduced at that size in a controlled trial.

The UCL 670 nm studies: colour contrast in people over 40

Glen Jeffery's group at University College London's Institute of Ophthalmology tested deep red 670 nm light on ageing eyes. In a 2020 study (Shinhmar et al., Journal of Gerontology), people aged 28-72 used 670 nm light. Younger participants showed no change, but those around 40 and older showed significant improvement in blue-axis (tritan) colour contrast sensitivity, and rod thresholds improved. Red-axis colour contrast improved but not significantly.

In 2021 (Shinhmar et al., Scientific Reports) the group reported that a single 3-minute 670 nm exposure improved cone colour contrast thresholds for about a week in people aged 37-70, and that timing mattered: the effect was found with morning exposure.

What to keep in mind: these were small studies, they measured colour contrast thresholds rather than sharpness of vision or eye disease, and they used a calibrated, low-energy light source. They are an interesting signal for healthy ageing eyes, not proof that home panels improve eyesight.

Myopia in children: real effect, real safety questions

The strongest randomized evidence for red light on the eye is in children with myopia. A multicentre randomized trial in China (Jiang et al., Ophthalmology 2022) enrolled 264 children aged 8-13 using a 650 nm desktop device for 3 minutes twice a day, 5 days a week. After 12 months, eye elongation was 0.13 mm with red light versus 0.38 mm with glasses alone, and no structural damage was seen on scans during the trial.

However, in 2023 JAMA Ophthalmology published a case report of retinal damage in a 12-year-old after repeated low-level red-light laser exposure for myopia (Liu et al.). Follow-up work also described some rebound after stopping treatment (Xiong et al., Clinical & Experimental Ophthalmology 2022). This is a medically supervised treatment for children, not evidence for adults using consumer devices.

LIGHTSITE and Valeda: the AMD trials

The most rigorous trials in older eyes are the LIGHTSITE trials of the Valeda Light Delivery System (590, 660 and 850 nm) in dry AMD. LIGHTSITE III was a randomized, double-masked, sham-controlled trial with 100 patients (148 eyes). At 13 months the treated group gained about 2.4 more letters on the eye chart than sham (Boyer et al., Retina 2024). The 24-month analysis reported a +6.2 letter gain and fewer eyes progressing to geographic atrophy (6.8% vs 24.0% with sham) (Jaffe et al., Retina 2026). Several authors are employees of or consultants to the device maker, LumiThera. LIGHTSITE II also reported benefits in a smaller randomized trial (Burton et al., Ophthalmology and Therapy 2023).

These results are for a medical device, used at a fixed protocol under supervision, in people with intermediate dry AMD. The gain is roughly one line on an eye chart, not a transformation of eyesight.

What is proven and what isn't

Reasonably supported:

A medical photobiomodulation device (Valeda) gives a modest vision gain in intermediate dry AMD in sponsor-linked randomized trials.
Supervised low-level red light slows eye elongation in myopic children in randomized trials.

Promising but unproven:

Brief 670 nm exposure improving colour contrast in healthy people over 40 (small studies, one lab).

'95-97% improved eyesight in two weeks' as a general claim. It comes from an uncontrolled case series in AMD patients.
Any evidence that consumer red light panels improve eyesight, reverse cataracts, or slow eye ageing.

Eye safety

Consumer red light panels are not eye devices. They are not designed, dosed or tested for treating the eye.
Don't stare into high-power LEDs or lasers. Bright light at close range can damage the retina, and a retinal injury has been reported even with a device made for myopia treatment.
Wear the eye protection supplied with a panel when treating your face or body.
If you have AMD, myopia, cataracts or any other eye condition, talk to an ophthalmologist before trying any light therapy on your eyes.

The bottom line

Red and near-infrared light for the eye is an active research area with some genuine results, mostly from medical devices used under supervision. The viral '95-97% in two weeks' claim leans on a single 2008 study without a proper control group. For healthy ageing eyes, the honest answer today is: interesting, not proven.